期刊文献+

黄体酮治疗黄体功能不全所致先兆流产的临床疗效探讨 被引量:6

Clinical Efficacy of Progesterone in the Treatment of Threatened Abortion Caused by Luteal Insufficiency
下载PDF
导出
摘要 目的:分析黄体酮治疗黄体功能不全所致先兆流产的临床疗效。方法:选取2016年5月—2017年5月我院收治的因黄体功能不全所致先兆流产100例患者为研究对象,按随机数字表法分为两组,各50例。两组均接受常规治疗,对照组给予绒毛膜促性腺激素(2 000 U,qod)治疗,观察组给予黄体酮注射液(20 mg,qd)治疗,2周后,比较两组疗效及不良反应发生情况。结果 :观察组治疗有效率明显高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论 :黄体酮治疗黄体功能不全所致先兆流产的疗效显著,安全性高,值得临床推广使用。 Objective: To analyze the clinical efficacy of progesterone in the treatment of threatened abortion caused by luteal insufficiency. Methods: 100 cases of patients with threatened abortion caused by luteal insufficiency admitted to our hospital from May 2016 to May 2017 were selected as subjects and divided into two groups according to the random number table method, 50 cases in each group. The patients in the two groups received routine treatment. The patients in the control group were given chorionic gonadotropin(2 000 U, qod), and the patients in the observation group were given progesterone injection(20 mg, qd). After 2 weeks of the treatment, the clinical efficacy and the occurrence of adverse reactions were compared between the two groups. Results: The effective rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant(P<0.05); there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Progesterone has significant clinical efficacy and high safety in the treatment of threatened abortion caused by luteal insufficiency, and is worthy of clinical use.
作者 胡萍 徐晓栋
出处 《中国执业药师》 CAS 2018年第8期15-16,20,共3页 China Licensed Pharmacist
关键词 黄体酮 黄体功能不全 先兆流产 安全性 Progesterone Luteal Insufficiency Threatened Abortion Safety
  • 相关文献

参考文献8

二级参考文献115

  • 1李近瑶,吴江平.黄体酮不同给药途径治疗妊娠早期先兆流产疗效比较[J].实用医药杂志,2013,30(12):1064-1066. 被引量:10
  • 2Devoto L, Fuentes A, Kohen P, et al. The human corpus luteum: life cycle and function in natural cycles. Fertil Steril, 2009, 92(3): 1067-79.
  • 3Chabbert Buffet N, Djakoure C, Maitre SC, et ai. Regulation of the human menstrual cycle, Front Neuroendocrinol, 1998, 19(3):151-86.
  • 4Szekeres-Bartho J, Wilczynski JR, Basta P, et al. Role of progesterone and progestin therapy in threatened abortion and preterm labour. Front Biosci, 2008, 13:1981-90.
  • 5Csapo AI, Pulkkinen MO, Wiest WG. Effects of lutectomy and progestreone replacement therapy in early pregnancy patients. Am J Obstet Gynecol, 1973, 115(6):759-65.
  • 6Messinis I, Messini C, Dafopoulos K. Luteal-phase endocrinology. Reprod Biomed Online, 2009, 19(4):4314.
  • 7Fatemi HM. The luteal phase after 3 decades of IVF: what do we know? Reprod Biomed Online, 2009, 19(4):4331.
  • 8Vaisbuch E, de Ziegler D, Leong M, et al. Luteal-phase support in assisted reproduction treatment: real-life practices reported world wide by an updated website-based survey. Reprod Biomed Online, 2014, 28(3):330-5.
  • 9Yanushpolsky E, Hurwitz S, Greenberg L, et al. Patterns ofluteal phase bleeding in in vitro fertilization cycles supple- mented with Crinone vaginal gel and with intramuscular progesterone-impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertil Steril, 2011, 95(2):617-20.
  • 10Darwish A. Enhancing Success of Assisted Reproduction. Rijeka: InTech, 2012:155-72.

共引文献393

同被引文献46

引证文献6

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部